Brandes Investment Partners LP Has $53.38 Million Holdings in Kenvue Inc. $KVUE

Brandes Investment Partners LP boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 25.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,094,648 shares of the company’s stock after purchasing an additional 632,903 shares during the quarter. Brandes Investment Partners LP owned 0.16% of Kenvue worth $53,383,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Elyxium Wealth LLC acquired a new position in Kenvue during the 4th quarter valued at $26,000. Physician Wealth Advisors Inc. raised its stake in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock valued at $26,000 after purchasing an additional 618 shares during the last quarter. SBI Securities Co. Ltd. raised its stake in Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock valued at $39,000 after purchasing an additional 1,027 shares during the last quarter. Leonteq Securities AG acquired a new position in Kenvue during the 4th quarter valued at $45,000. Finally, Hantz Financial Services Inc. raised its stake in Kenvue by 157.2% during the 3rd quarter. Hantz Financial Services Inc. now owns 2,850 shares of the company’s stock valued at $46,000 after purchasing an additional 1,742 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 2.0%

KVUE opened at $17.91 on Wednesday. The firm’s 50-day simple moving average is $17.38 and its 200-day simple moving average is $17.51. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $22.87. The firm has a market cap of $34.38 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.33 and a beta of 0.54.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same quarter in the prior year, the firm earned $0.24 EPS. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. Equities research analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were issued a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. Kenvue’s dividend payout ratio is presently 97.65%.

Insider Buying and Selling at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 1.59% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on KVUE. Canaccord Genuity Group upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. UBS Group cut their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Argus upgraded shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Zacks Research raised shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, May 8th. Finally, Citigroup lowered their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, April 15th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.